The activation of PI3K/Akt signaling mediates the acquired resistance to sorafenib in hepatocellular carcinoma (HCC) cells [9]; PTEN over-expression enhances the sensitivity of HCC cells to the anti-proliferative and pro-apoptotic effects of sorafenib [10]. Here, AKT1 is linked to hepatocellular carcinoma.